应用碳纳米粒子混悬液进行早期乳腺癌前哨淋巴结定位：一项回顾性队列研究。
Application of a carbon nanoparticle suspension for sentinel lymph node mapping in patients with early breast cancer: a retrospective cohort study.
机构信息
Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
出版信息
World J Surg Oncol. 2018 Jun 19;16(1):112. doi: 10.1186/s12957-018-1414-6.
BACKGROUND
To stage axillary lymph nodes in women with early-stage breast cancer, sentinel lymph node biopsy (SLNB), rather than axillary lymph node dissection (ALND), has been employed. Moreover, different tracer methods have various advantages and disadvantages. In recent years, carbon nanoparticle suspensions (CNSs) have been used as lymph node tracers during surgeries for thyroid cancer, gastric cancer, and colorectal cancer. The study retrospectively analyzed the feasibility and accuracy of CNS for sentinel lymph node (SLN) mapping in patients with early breast cancer.
METHODS
This single-center, retrospective study included breast cancer patients who underwent SLNB from January 1, 2016, to December 31, 2017, in the Department of Breast Cancer, Guangdong General Hospital. All patients received standard SLNB surgery using a CNS tracer.
RESULTS
A total of 332 cases were included in this study. The SLN identification rate was 99.1% (329/332), and the mean number of SLNs was 2.6 (range, 1-6). SLN metastasis was found in 62 (18.8%) cases, of which 90.3% were found to be macrometastases. The sensitivity of SLNB was 95.9% (47/49), with a specificity of 100% (42/42), a positive predictive value of 100% (47/47), a negative predictive value of 95.5% (42/44), and a false-negative rate of 4.1% (2/49).
CONCLUSION
The identification and predictive values of a CNS tracer for SLNB were satisfactory.
背景
对于早期乳腺癌患者的腋窝淋巴结分期，采用前哨淋巴结活检（SLNB）而非腋窝淋巴结清扫术（ALND）。此外，不同示踪剂方法各有优缺点。近年来，碳纳米粒子混悬液（CNS）已用于甲状腺癌、胃癌和结直肠癌的手术中作为淋巴结示踪剂。本研究回顾性分析了 CNS 在前哨淋巴结（SLN）定位中的可行性和准确性在早期乳腺癌患者中的应用。
方法
这项单中心、回顾性研究纳入了 2016 年 1 月 1 日至 2017 年 12 月 31 日在广东总医院乳腺科行 SLNB 的乳腺癌患者。所有患者均采用 CNS 示踪剂行标准 SLNB 手术。
结果
共纳入 332 例患者。SLN 识别率为 99.1%（329/332），平均 SLN 数量为 2.6 个（范围为 1-6）。62 例（18.8%）发现 SLN 转移，其中 90.3%为宏转移。SLNB 的灵敏度为 95.9%（47/49），特异性为 100%（42/42），阳性预测值为 100%（47/47），阴性预测值为 95.5%（42/44），假阴性率为 4.1%（2/49）。
结论
CNS 示踪剂用于 SLNB 的识别和预测价值令人满意。
Zotero 插件